Lactobacillus rhamnosus GG 관련 Antibiotic-Associated Diarrhea (AAD)
AMeta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
결론
Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.
Key Study Findings
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
vs: None
Outcome: Probiotic prescribing habits of Italian PCPs
효과: L. rhamnosus GG used by 91.8%
None
대상 집단: Italian primary care pediatricians
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
vs: None
Outcome: Clinical guideline recommendations for pediatric GI
효과: None
None
대상 집단: Pediatric patients with GI disorders
Controlled Clinical Trial
n=24
2 weeks
Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in …
Dose: 10^9 CFU/day for 14 days
vs: LPS-only group (no probiotics)
Outcome: Cardiac damage markers (CK-MB, cTn-I, cytokines)
효과: None
p<0.05 to <0.001
대상 집단: Male Wistar albino rats with LPS-induced sepsis
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: Pediatric population
Randomized Controlled Trial
Double-blind
A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea …
Dose: Probiotics (multi-strain)
vs: Placebo
Outcome: Antibiotic-associated diarrhea incidence
효과: None
None
대상 집단: Adult patients receiving antibiotics
Review
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
Dose: S. boulardii CNCM I-745
vs: Placebo or standard care
Outcome: AAD prevention and pediatric gastroenteritis
효과: None
None
대상 집단: AAD and gastroenteritis patients (review)
Key Statistics
20
연구
4000
참여자
↑
Positive
A
등급
Referenced Papers
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 인용
Medicina (Kaunas, Lithuania)
2025
1 인용
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Cureus
2024
1 인용
Cureus
2023
19 인용
Archivos argentinos de …
2022
23 인용
Canadian journal of …
2022
6 인용
International journal of …
2020
32 인용
Pediatric gastroenterology, hepatology …
2020
20 인용
Pharmacological research
2018
132 인용
A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands.
Meta-Analysis
BMC gastroenterology
2018
80 인용
United European gastroenterology …
2018
66 인용
Probiotics and antimicrobial …
2018
26 인용
World journal of …
2017
68 인용
Journal of pediatric …
2016
233 인용
Digestive diseases (Basel, …
2016
37 인용
The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts.
Systematic Review
Paediatric drugs
2015
122 인용
Journal of clinical …
2015
35 인용
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 인용
Nutricion hospitalaria
2015
5 인용
Medycyna wieku rozwojowego
2012
1 인용
Current opinion in …
2009
82 인용
Advances in biochemical …
2008
535 인용
The Journal of …
2007
265 인용
The American journal …
2006
918 인용
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 인용
Inflammation
2002
37 인용
The American journal …
2001
648 인용
Inflammation
2001
101 인용
The Journal of …
1999
559 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 10-20 billion CFU/day
- ibssupport:
- 10 billion CFU/day for 4-8 weeks
- aadprevention:
- 10-20 billion CFU/day (start with antibiotic, continue 7 days after)
상한량: Generally well-tolerated up to 40 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Mixed | 279 |
| None | -- | Positive | -- |
| 10^9 CFU/day for 14 days | 2 weeks | Positive | 24 |
| None | -- | Mixed | -- |
| Probiotics (multi-strain) | -- | Positive | -- |
| S. boulardii CNCM I-745 | -- | Positive | -- |
| None | -- | Positive | -- |
| Twice daily | -- | Neutral | 2650 |
권장 복용 시간: On an empty stomach or 30 minutes before meals for optimal survival
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
- ⚠ Rare reports of bacteremia in severely immunocompromised individuals
- ⚠ Occasional loose stools during adjustment period
- ⚠ Very rare: systemic infection in critically ill patients with central venous catheters
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk of infection in immunocompromised patients)
- ● Antifungals (no known interaction but may affect gut flora balance)
일일 최대 섭취 허용량: Generally well-tolerated up to 40 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Lactobacillus rhamnosus GG help with Antibiotic-Associated Diarrhea (AAD)?
Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that Lactobacillus rhamnosus GG may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Lactobacillus rhamnosus GG should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Antibiotic-Associated Diarrhea (AAD)
Lactobacillus rhamnosus GG 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.